The 7 references in paper Editorial article , Редакционная статья (2015) “Резолюция по итогам Экспертного совета «Современные подходы к лечению дифференцированного рака щитовидной железы, резистентного к терапии радиоактивным йодом» // Current approaches to therapy for radioactive iodine therapy-resistant differentiated thyroid cancer: Expert council resolution on overall results” / spz:neicon:ogsh:y:2015:i:3:p:59-63

1
Румянцев П.О., Фомин Д.К., Румянцева У.В. Критерии резистентности высокодифференцированного рака щитовидной железы к терапии радиоактивным йодом. Опухоли головы и шеи
(check this in PDF content)
2
14;3:4–9. [Rumyantsev P.О., Fomin D.K., Rumyantseva U.V. Criteria of the resistance of the high differentiated thyroid gland carcinoma to the active iodine therapy. Opukholi golovy i shei = Head and Neck Tumors 2014;3:4–9. (In Russ.)]. 2. Cooper D.S., Doherty G.M., Haugen B.R. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2009;19(11):1167–214.
(check this in PDF content)
3
Pacini F., Schlumberger M.G., Dralle H. et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154(6):787–803.
(check this in PDF content)
4
Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant meta stases from papillary and follicular thyroid carci noma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892–9.
(check this in PDF content)
5
Elisei R., Schlumberger M.G.,Tahara M. et al. Subgroup Analyses of a phase 3, multicen ter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer. Presented at the Annual Congress of the European Society for Medical Oncology. September, 29, 2014. Madrid, Spain.
(check this in PDF content)
6
Brose M.S., Nutting C.M., Jarzab B. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384(9940): 319–28.
(check this in PDF content)
7
Schlumberger M.G., Tahara M., Wirth L.J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372(7):621–30.
(check this in PDF content)